DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21303/S-032
NDA 21977/S-043

**SUPPLEMENT APPROVAL**

Shire Development LLC
Attention: Peggy Sung
Manager, Global Regulatory Affiars
300 Shire Way
Lexington, MA 02421

Dear Ms. Sung:

Please refer to your Supplemental New Drug Application (sNDA) dated January 3, 2017, received January 3, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Adderall XR (dextroamphetamine mixed salts of a single entity amphetamine product) 5mg, 10mg, 15mg, 20mg, 25mg, 30mg capsules and Vyvanse (lisdexamfetamine dimesylate) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.

We also refer to our letter dated September 21, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for all Amphetamine products. This information pertains to the association between the use of amphetamines and serotonin syndrome.

These prior approval supplemental new drug applications provide for revisions to the labeling for Adderall XR and Vyvanse consistent with our September 21, 2016 letter. Additional reference is made to your rebuttal response (change not warranted) letter dated and received on October 21, 2016. Further reference is made to email correspondences negotiating labeling language with Dr. Ermias Zerislassie, dated December 21, 2016, and your final submission dated January 3, 2017, complying with this Safety Labeling Change (SLC).

## APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your January 3, 2017, submission includes final printed labeling (FPL) for your package insert, and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Latrice Wilson, Regulatory Project Manager, at (240) 402-5317 latrice.wilson@fda.hhs.gov.

Sincerely,

*{See appended electronic signature page}*

Mitchell V. Mathis, MD
Division Director
Division of Psychiatry
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

MITCHELL V Mathis
01/06/2017